New Research Uses Decoy to Activite the Immune System
According to an exciting story on ABC television's Bay Area affiliate, researchers at Stanford University think they've found a way to 'wake up' the immune system of lymphoma patients and get it to recognize and attack cancerous tumors.
Their method involves injecting DNA bioengineered to resemble bacteria directly into the tumor, which acts like a decoy that alerts the immune system into going after it and, once it gets there, attacking the lymphoma cells as well.
The hope is that this method can work something like a vaccine and prevent the cancer from coming back.
This is a very promising development for people suffering from lymphomas, and Stanford is currently recruiting people with recurrent low-grade lymphomas to take part in this study. You can learn more about it by visiting the study's Clinical Trials page, found here.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
